Effects of combined MAO-B inhibitors and levodopa vs monotherapy in Parkinson's disease

Frontiers in Aging Neuroscience

Volumn 6, Issue JUL, 2014, Pages

  Krishna, Rakhee ^a   Ali, Manal ^b   Moustafa, Ahmed A ^c  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c WESTERN SYDNEY UNIVERSITY   (Australia)

Author keywords

Anxiety; Cognition; Depression; Learning; MAO inhibitors; Parkinson's disease; Quality of life; Working memory

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE;

AGED; AKINESIA; ANXIETY; APATHY; ARTICLE; ATTENTION; BASAL GANGLION; BEHAVIOR DISORDER; CLINICAL ARTICLE; COGNITION; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; EXECUTIVE FUNCTION; FEMALE; HUMAN; LEARNING; MALE; MEMORY; MONOTHERAPY; PARKINSON DISEASE; QUALITY OF LIFE; RECALL; STIMULATION; TREMOR; WORKING MEMORY;

EID: 84904621242     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00180     Document Type: Article

References (85)

1. Amsterdam, J. D., & Bodkin, J. A. (2006). Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol, 26(6), 579-586.
2. Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988). An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol, 56(6), 893-897.
3. Birkmayer, W., Riederer, P., Youdim, M. B., & Linauer, W. (1975). The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm, 36(3-4), 303-326.
4. Bodkin, J. A., & Amsterdam, J. D. (2002). Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry, 159(11), 1869-1875.
5. Bright, P., Jaldow, E., & Kopelman, M. D. (2002). The National Adult Reading Test as a measure of premorbid intelligence: a comparison with estimates derived from demographic variables. J Int Neuropsychol Soc, 8(6), 847-854.
6. Burn, D. J., Rowan, E. N., Allan, L. M., Molloy, S., O'Brien, J. T., & McKeith, I. G. (2006). Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. Journal of Neurology, Neurosurgery, & Psychiatry, 77(5), 585-589.
7. Caslake, R., Macleod, A., Ives, N., Stowe, R., & Counsell, C. (2009). Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database Syst Rev(4), CD006661.
8. Cohen, J. D., Perlstein, W. M., Braver, T. S., Nystrom, L. E., Noll, D. C., Jonides, J., et al. (1997). Temporal dynamics of brain activation during a working memory task. Nature, 386(6625), 604-608.
9. Colman, K. S., Koerts, J., van Beilen, M., Leenders, K. L., Post, W. J., & Bastiaanse, R. (2009). The impact of executive functions on verb production in patients with Parkinson's disease. Cortex, 45(8), 930-942.
10. Dalrymple-Alford, J. C., Jamieson, C. F., & Donaldson, I. M. (1995). Effects of selegiline (deprenyl) on cognition in early Parkinson's disease. Clin Neuropharmacol, 18(4), 348-359.
11. Delis, D. C., Kramer, J. H., Kaplan, E., & Ober, B. A. (1987). The California Verbal Learning Test. San Antonio, TX: Psychological Corporation.
12. Dewey, R. B., Jr. (2004). Management of motor complications in Parkinson's disease. Neurology, 62(6 Suppl 4), S3-7.
13. Domellof, M. E., Elgh, E., & Forsgren, L. (2011). The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson's disease. Movement Disordors, 26(12), 2183-2189.
14. Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000). The FAB: a Frontal Assessment Battery at bedside. Neurology, 55(11), 1621-1626.
15. Ecker, D., Unrath, A., Kassubek, J., & Sabolek, M. (2009). Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study. BMC Neurology, 9, 23.
16. Elmer, L., Schwid, S., Eberly, S., Goetz, C., Fahn, S., Kieburtz, K., et al. (2006). Rasagilineassociated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci, 248(1-2), 78-83.
17. Fabbrini, G., Abbruzzese, G., Marconi, S., & Zappia, M. (2012). Selegiline: a reappraisal of its role in Parkinson disease. Clin Neuropharmacol, 35(3), 134-140.
18. Fahn, S., & Chouinard, S. (1998). Experience with tranylcypromine in early Parkinson's disease. J Neural Transm Suppl, 52, 49-61.
19. Farooqui, A. A., Bhutani, N., Kulashekhar, S., Behari, M., Goel, V., & Murthy, A. (2011). Impaired conflict monitoring in Parkinson's disease patients during an oculomotor redirect task. Experimental Brain Research, 208(1), 1-10.
20. Feiger, A. D., Rickels, K., Rynn, M. A., Zimbroff, D. L., & Robinson, D. S. (2006). Selegiline transdermal system for the treatment of major depressive disorder: an 8- week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry, 67(9), 1354-1361.
21. Giladi, N., Shabtai, H., Simon, E. S., Biran, S., Tal, J., & Korczyn, A. D. (2000). Construction of freezing of gait questionnaire for patients with Parkinsonism. Parkinsonism Relat Disord, 6(3), 165-170.
22. Goldman, J. G., & Holden, S. (2014). Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol, 16(3), 281.
23. Grace, A. A. (2008). Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Mov Disord, 23 Suppl 3, S560-569.
24. Hamon, M., & Blier, P. (2013). Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry, 45, 54-63.
25. Hanagasi, H. A., Gurvit, H., Unsalan, P., Horozoglu, H., Tuncer, N., Feyzioglu, A., et al. (2011). The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord, 26(10), 1851-1858.
26. Heaton, S. K., Chelune, G. J., Talley, J. L., Kay, G. G., & Curtiss, G. (1993). Wisconsin Card Sorting Test manual: Revised and expanded. Odessa, FL: Psychological Assessment Resources.
27. Henchcliffe, C., Schumacher, H. C., & Burgut, F. T. (2005). Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert Rev Neurother, 5(6), 811-821.
28. Hietanen, M. H. (1991). Selegiline and cognitive function in Parkinson's disease. Acta Neurol Scand, 84(5), 407-410.
29. Hindmarch, I., Alford, C., Barwell, F., & Kerr, J. S. (1992). Measuring the side effects of psychotropics: the behavioural toxicity of antidepressants. J Psychopharmacol, 6(2), 198-203.
30. Hobson, P., Gallacher, J., & Meara, J. (2005). Cross-sectional survey of Parkinson's disease and parkinsonism in a rural area of the United Kingdom. Movement Disordors, 20(8), 995-998.
31. Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: onset, progression and mortality. Neurology, 17(5), 427-442.
32. Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., et al. (1990). Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology, 40(10), 1529-1534.
33. Jankovic, J., & Stacy, M. (2007). Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs, 21(8), 677-692.
34. Jenkinson, C., Peto, V., Fitzpatrick, R., Greenhall, R., & Hyman, N. (1995). Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ- 39). Age Ageing, 24(6), 505-509.
35. Johnson, S., Tazik, S., Lu, D., Johnson, C., Youdim, M. B., Wang, J., et al. (2010). The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis. Front Neurosci, 4, 180.
36. Kassubek, J., Juengling, F. D., Hellwig, B., Spreer, J., & Lucking, C. H. (2002). Thalamic gray matter changes in unilateral Parkinsonian resting tremor: a voxel-based morphometric analysis of 3-dimensional magnetic resonance imaging. Neuroscience Letters, 323(1), 29-32.
37. Kieburtz, K., McDermott, M., Como, P., Growdon, J., Brady, J., Carter, J., et al. (1994). The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group. Neurology, 44(9), 1756-1759.
38. Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988). Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. The New England Journal of Medicine, 318(14), 876-880.
39. Korchounov, A., Winter, Y., & Rossy, W. (2012). Combined beneficial effect of rasagiline on motor function and depression in de novo PD. Clin Neuropharmacol, 35(3), 121- 124.
40. Kupershmidt, L., Amit, T., Bar-Am, O., Weinreb, O., & Youdim, M. B. (2012). Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice. Mol Neurobiol, 46(1), 217-220.
41. Lyros, E., Messinis, L., & Papathanasopoulos, P. (2008). Does motor subtype influence neurocognitive performance in Parkinson's disease without dementia? European Journal of Neurology, 15(3), 262-267.
42. Marin, R. S., Biedrzycki, R. C., & Firinciogullari, S. (1991). Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res, 38(2), 143-162.
43. Moustafa, Bell, P., Eissa, A. M., & Hewedi, D. H. (2013). The effects of clinical motor variables and medication dosage on working memory in Parkinson's disease. Brain Cogn, 82(2), 137-145.
44. Moustafa, Cohen, Sherman, & Frank. (2008). A role for dopamine in temporal decision making and reward maximization in parkinsonism. Journal of Neuroscience, 28(47), 12294-12304.
45. Moustafa, Sherman, S. J., & Frank, M. J. (2008). A dopaminergic basis for working memory, learning and attentional shifting in Parkinsonism. Neuropsychologia, 46(13), 3144- 3156.
46. Mure, H., Hirano, S., Tang, C. C., Isaias, I. U., Antonini, A., Ma, Y., et al. (2011). Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage, 54(2), 1244-1253.
47. Muriel, M. P., Orieux, G., & Hirsch, E. C. (2002). Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats. Mov Disord, 17(6), 1174-1179.
48. Nayak, L., & Henchcliffe, C. (2008). Rasagiline in treatment of Parkinson's disease. Neuropsychiatr Dis Treat, 4(1), 23-32.
49. Nickel, B., Schulze, G., & Szelenyi, I. (1990). Effect of enantiomers of deprenyl (selegiline) and amphetamine on physical abuse liability and cortical electrical activity in rats. Neuropharmacology, 29(11), 983-992.
50. Nyholm, D. (2007). The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord, 13 Suppl, S13-17.
51. O'Carroll, A. M., Fowler, C. J., Phillips, J. P., Tobbia, I., & Tipton, K. F. (1983). The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol, 322(3), 198-202.
52. Oh, J. Y., Kim, Y. S., Choi, B. H., Sohn, E. H., & Lee, A. Y. (2009). Relationship between clinical phenotypes and cognitive impairment in Parkinson's disease (PD). Archives of Gerontology and Geriatrics, 49(3), 351-354.
53. Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., et al. (2009). A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med, 361(13), 1268-1278.
54. Owen, A. M., McMillan, K. M., Laird, A. R., & Bullmore, E. (2005). N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp, 25(1), 46-59.
55. Parkinson Study Group. (1993). Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med, 328(3), 176-183.
56. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol, 59(12), 1937-1943.
57. Perlstein, W. M., Dixit, N. K., Carter, C. S., Noll, D. C., & Cohen, J. D. (2003). Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia. Biol Psychiatry, 53(1), 25-38.
58. Piray, P., Zeighami, Y., Bahrami, F., Eissa, A. M., Hewedi, D. H., & Moustafa, A. A. (2014). Impulse control disorders in Parkinson's disease are associated with dysfunction in stimulus valuation but not action valuation. J Neurosci, 34(23), 7814-7824.
59. Poletti, M., Frosini, D., Pagni, C., Baldacci, F., Nicoletti, V., Tognoni, G., et al. (2012). Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drugnaive patients with Parkinson's disease. Journal of Neurology, Neurosurgery, & Psychiatry, 83(6), 601-606.
60. Portin, R., & Rinne, U. K. (1983). The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment. Acta Neurol Scand Suppl, 95, 135-144.
61. Probst-Cousin, S., Druschky, A., & Neundorfer, B. (2003). Disappearance of resting tremor after "stereotaxic" thalamic stroke. Neurology, 61(7), 1013-1014.
62. Reitan, R. M., & Wolfson, D. (1985). The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation. Tucson, Ariz.: Neuropsychology Press.
63. Riederer, P., & Laux, G. (2011). MAO-inhibitors in Parkinson's Disease. Exp Neurobiol, 20(1), 1-17.
64. Riggeal, B. D., Crucian, G. P., Seignourel, P., Jacobson, C. E., Okun, M. S., Rodriguez, R., et al. (2007). Cognitive decline tracks motor progression and not disease duration in Parkinson patients. Neuropsychiatric Disease and Treatment, 3(6), 955-958.
65. Rinne, U. K. (1987). Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology, 37(5), 826-828.
66. Robottom, B. J. (2011). Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. Patient Prefer Adherence, 5, 57-64.
67. Silverdale, M. (2007). Continuous dopaminergic stimulation in Parkinson's disease. Progress in Neurology and Psychiatry, 11(1), 24-28.
68. Smulders, K., van Nimwegen, M., Munneke, M., Bloem, B. R., Kessels, R. P., & Esselink, R. A. (2012). Involvement of specific executive functions in mobility in Parkinson's disease.Parkinsonism Relat Disord.
69. Steur, E. N., & Ballering, L. A. (1997). Moclobemide and selegeline in the treatment of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry, 63(4), 547.
70. Stocchi, F., Tagliati, M., & Olanow, C. W. (2008). Treatment of levodopa-induced motor complications. Mov Disord, 23 Suppl 3, S599-612.
71. Stroop, J. R. (1935). Studies of interference in serial verbal reactions. . Journal of Experimental Psychology, 18, 643-662.
72. Talati, R., Reinhart, K., Baker, W., White, C. M., & Coleman, C. I. (2009). Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord, 15(7), 500-505.
73. Troyer, A. K., Moscovitch, M., & Winocur, G. (1997). Clustering and switching as two components of verbal fluency: evidence from younger and older healthy adults. Neuropsychology, 11(1), 138-146.
74. Trugman, J. M., James, C. L., & Wooten, G. F. (1991). D1/D2 dopamine receptor stimulation by L-dopa. A [14C]-2-deoxyglucose autoradiographic study. Brain, 114 ( Pt 3), 1429- 1440.
75. Vakil, E., & Herishanu-Naaman, S. (1998). Declarative and procedural learning in Parkinson's disease patients having tremor or bradykinesia as the predominant symptom. Cortex, 34(4), 611-620.
76. Vandenbossche, J., Deroost, N., Soetens, E., Zeischka, P., Spildooren, J., Vercruysse, S., et al. (2012). Conflict and freezing of gait in Parkinson's disease: support for a response control deficit. Neuroscience, 206, 144-154.
77. Wechsler. (1987). Wechsler Memory Scale-Revised. San Antonio, TX: Psychological Corporation.
78. Wechsler, D. (1958). The measurement and appraisal of adult intelligence (4th ed.). Baltimore,: Williams & Wilkins.
79. Weinberger, M., Hutchison, W. D., Lozano, A. M., Hodaie, M., & Dostrovsky, J. O. (2009). Increased gamma oscillatory activity in the subthalamic nucleus during tremor in Parkinson's disease patients. Journal of Neurophysiology, 101(2), 789-802.
80. Weintraub, D., Koester, J., Potenza, M. N., Siderowf, A. D., Stacy, M., Voon, V., et al. (2010). Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology, 67(5), 589-595.
81. Wylie, S. A., van den Wildenberg, W., Ridderinkhof, K. R., Claassen, D. O., Wooten, G. F., & Manning, C. A. (2012). Differential susceptibility to motor impulsivity among functional subtypes of Parkinson's disease. Journal of Neurology, Neurosurgery, & Psychiatry.
82. Yasar, S., Goldberg, J. P., & Goldberg, S. R. (1996). Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. J Neural Transm Suppl, 48, 61-73.
83. Youdim, M. B. (2006). The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res, 3(5), 541-550.
84. Youdim, M. B. (2013). Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline. Exp Neurobiol, 22(1), 1-10.
85. Zaidel, A., Arkadir, D., Israel, Z., & Bergman, H. (2009). Akineto-rigid vs. tremor syndromes in Parkinsonism. Current Opinion in Neurology, 22(4), 387-393.